Moderna’s vaccine now surpasses the Pfizer / BioNTech vaccine in effectiveness, according to a new study released Friday by the Centers for Disease Prevention and Control (CDC).
According to information from the largest American health agency, the Moderna vaccine would better protect against the serious effects of the coronavirus in the long term.
The CDC was based on a study on a sample of nearly 3,700 adults hospitalized in the United States, for a Covid-19 with severe symptoms. It took place between March 11 and August 15, 2021, when the United States experienced a predominance of the Delta variant around mid-July, but also before when it was the Alpha variant that was predominant.
The results show that the Pfizer vaccine lost long-term efficacy from 91% over the 14-120 day period after injection to 77% over the 120-day period, while Moderna increased from 93% to 92% over the same period studied.
Against hospitalizations, Pfizer’s vaccine is 88% effective, Johnson & Johnson’s vaccine is 68% effective, and Moderna 93%.
These results appear to correspond to a significant efficacy trend for the Moderna vaccine, which has been observed in the results of other studies conducted in the United States. On another study conducted on 180,000 people vaccinated in Minnesota between January and July 2021, this vaccine shows an efficacy of 76% against the Delta variant, and 42% for the Pfizer vaccine.
Moderna, which will regain more interest now that its vaccine appears to be more effective than Pfizer (the most widely used in Western countries), is now working on a new type of combination vaccine that protects not only against coronavirus but also against seasonal flu. The laboratory is not the only one to work on this concept, other competitors like Novavax, are in the process of developing this type of vaccine.